JNJ weekly analysis: overbought technicals highlight stretched rally

Traders Union
All News
Financial News
Johnson & Johnson up 4.86% this week

Highlights

Johnson & Johnson (JNJ) trades at $238.16, significantly above MA-20 ($219.96), MA-50 ($211.91), and MA-200 ($180.86), signaling strong multi-timeframe bullish momentum.
Momentum indicators including MACD, ADX, and Awesome Oscillator remain bullish, but extreme overbought signals are present with RSI at 82.94 and Stochastic RSI at 100.00.
Nearest support lies at the Ichimoku Kijun ($218.37) and MA-50 ($211.91), while upside resistance is at $241.00, with an 80%+ probability of further price increases in the next five days.

Dividend, MedTech launches boost sentiment as institutional flows shift

Johnson & Johnson declared a quarterly dividend of $1.30 per share, payable on March 10, 2024, to shareholders of record as of February 24, 2024. The company also unveiled new developments in its MedTech and oncology divisions, including product launches and clinical updates supporting its growth strategy. Recent changes in institutional holdings were noted during the quarter.

Overbought signals emerge as weekly momentum accelerates

Weekly technical analysis shows strong upside momentum above all major moving averages, with dynamic support from the Ichimoku Kijun at $218.37 and additional support from the MA-50 at $211.91. Resistance is forming near the current high of $239.57, with the next threshold at $241.00, while initial weekly support is located at $235.50. The RSI W1 is extremely elevated at 82.94, Stochastic RSI is at 100.00, and the CCI also signals overbought conditions, all reflecting a stretched market, though trend indicators such as MACD, ADX, and the Awesome Oscillator continue to confirm robust bullish momentum.

Further gains likely next week as overextension raises retracement risk

For the coming five to seven trading days, JNJ is expected to consolidate between $235.50 and $241.00, with a strong bias toward further gains based on overwhelming bullish momentum and multi-timeframe trend alignment. A breakout above $241.00 could prompt further upside, while a sustained move below $235.50 could put retracement toward lower moving averages into play. The upside scenario remains favored, but extremely overbought readings warrant vigilance for a possible cooling period.

Parshwa Turakhiya, analyst, notes that Johnson & Johnson maintained remarkable bullish momentum this week, pushing decisively above all its key moving averages. He sees strong sentiment underpinned by the recent dividend announcement and encouraging MedTech and oncology updates. Technicals reveal clear overbought conditions, yet the uptrend remains intact and supported by multiple indicators. The analyst expects price action to consolidate between $235.50 and $241.00, with buyers maintaining an edge unless $235.50 breaks. "I’m staying vigilant for any cooling off, but the current setup still favors holding a bullish bias as long as momentum and news flow remain strong."

Previously it was reported that Johnson & Johnson is maintaining a strong uptrend, trading well above all major moving averages, with bullish signals from MACD and ADX while technical indicators such as RSI and Stochastic RSI reflect overbought conditions. The stock faces resistance near $230 and support at the Ichimoku Kijun line, suggesting consolidation is likely as upside is capped by extreme momentum readings.

Source of Data: JNJ Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.